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Background: Tetrandrine is a natural chemical product purified from fourstamen stephania root which recently has
been shown to act similarly as synthesized drug efflux pump inhibitor verapamil. The aim of the study is to
examine whether tetrandrine could potentiate anti-tubercular drugs to which Mycobacterium tuberculosis (MTB) has
turned resistant via efflux mechanisms.
Methods: We screened 200 MTB clinical isolates using drug sensitivity test to look for those who have turned
resistant to the drugs most probably due to efflux mechanisms. We found 29 isoniazid (INH) and ethambutol (EMB) -
dual resistant (IEDR) strains. Then we tested if treatment with tetrandrine or verapamil could reverse drug resistance to
INH and/or EMB in IEDR isolates.
Results: There is a parallel resistance among EMB- and INH-resistant strains in the tested clinical isolates. Among INH-
resistant strains, 65% was also EMB-resistant. This suggests an involvement of efflux mechanisms which can lead to dual
drug resistance in IEDR clinical isolates. Similar to a synthesized efflux pump inhibitor verapamil, tetrandrine treatment
together with INH or EMB brought down the MICs from the clinical level of drug resistance to the sensitive range of
both drugs. The effective rate reached 82% among IEDR clinical isolates.
Conclusions: Combinational application of tetrandrine with INH or EMB increased drug efficacy. Drugs like tetrandrine
may help to reduce drug dosage thus alleviate side effects.
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Due to the emergence of drug-resistance, many anti-
tubercular drugs end up not useful anymore [1]. An ur-
gent goal of anti-tubercular drug discovery is to find
drugs that can help to overcome drug resistance [1].
Drug resistance in MTB rises mostly from chromosomal
mutations. Such mutations were not found in some
drug-resistant clinical strains, where efflux mechanisms
may be held accountable [1-6]. Efflux pumps can pump
out toxic compounds of a variety of structures. This is
because efflux pumps have an extremely large central* Correspondence: ljli@zju.edu.cn
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unless otherwise stated.cavity, which allows binding of different ligands using a
different subset of pump residues through hydrophobic,
aromatic stacking and van der Waals interactions [3,7].
Thus it is easy to see why efflux pumps may mediate sim-
ultaneous drug resistance to drugs of various structures.
Tetrandrine (6,6',7,12-tetramethoxy-2,2'-dimethylberbam,
TET) is a low-toxicity drug extracted from the plant Ste-
phania tetrandra S. Moore (Fenfangji) of the menisperma-
ceae. It has been used in the treatment of hypertension,
cardiac arrhythmia and angina pectoris in China since the
1950s and few side effects have been noted in the clinical
practice [8]. TET has been shown to be a Ca2+ channel
antagonist. It interacts with the voltage-activated L-type
and T-type Ca2+ channels and the slowly gating K (Ca2+)
channel with varying degrees of specificity and affinity.
The binding site is located at the benzothiazepine receptor
on the alpha 1-subunit of the channel [8,9]. Recent studiesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pumps in a large range of life forms. It has a reversal effect
in P- glycoprotein-mediated drug resistance in cancer cells
[10]. It has a synergistic effect on drugs against fungus
Candida albicans, bacteria methicillin-resistant Staphylo-
coccus aureus, and Mycobacterium smegmatis [11-13].
Research has showed that efflux pumps across both pro-
karyotes and eukaryotes are very similar in structures and
functions [14]. Strikingly, bacterial efflux pump LmrA was
able to functionally complement human efflux pump
P-glycoprotein in human lung fibroblast cells [15].
Whatsmore, TET has been shown to have effects parallel-
ing those known calcium antagonists and synthesized ef-
flux pump inhibitors such as verapamil [8]. Based on this
amount of information, we can come to a hypothesis that
TET may be able to reverse efflux mechanism-mediated
drug resistance in MTB. Despite of the relatively large
body of literature pointing to this hypothesis, there have
not been any experiments to test it. This study shows the
effectiveness of TET in the reversal of drug resistance in a
group of IEDR MTB clinical isolates.
Methods
Bacterial strains and growth conditions
MTB were the clinical isolates from State Key Labora-
tory for Diagnosis and Treatment of Infectious Diseases
(SKL, Hangzhou, Zhejiang, China). H37Rv (Mycobacter-
ium tuberculosis ATCC®25618) was bought from ATCC.
The isolates and H37Rv were grown in KaiBiLi modified
Lowenstein-Jensen medium (Hangzhou Genesis Biode-
tection & Biocontrol CO., Ltd., Hangzhou, Zhejiang,
China).
Drugs
TET (potency ≥ 98%) and Rifampicin (97%) were pur-
chased from Aladdin Chemistry Co. Ltd (Shanghai,
China). 20 mg TET was dissolved in 800 μl PBS mixed
with three drops of hydrochloric acid. Let sit for 5 mi-
nutes until transparency appears, then add three drops
of 4% sodium hydroxide to neutralize the solution. Dis-
solved TET was further diluted in Middlebrook 7H9
broth to obtain desired concentration. PBS was made by
Hangzhou Ke Yi Biotechnology (Hangzhou, China).
INH, EMB and resazurin sodium salt were bought from
Sigma-Aldrich (St. Louis, MO, USA). Streptomycin at
USP grade was bought from Jing Ke Hong Da Biotech-
nology (Beijing, China).
Drug sensitivity assay
Drug sensitivity was measured in 96-well format as pre-
viously described and results have been shown to be
comparable with those obtained with the conventional
proportion method on Lowenstein-Jensen medium [16]. A
100 μl volume of Middlebrook 7H9 broth was dispensedin each well of a 96-well cell culture plate (Corning Incor-
porated, Corning, NY, USA). Two-fold dilutions of the
first-line anti-mycobacterial drugs were directly prepared
in the medium. About 1 mg bacteria were put in 800 μl
7H9 broth in a 2-ml test tube containing two 3 mm glass-
beads. Bacteria suspensions were prepared by shaking the
tube at the highest speed for 1 hour on a shaker from
Extractor™ 36 produced by CapitalBio Corporation (Beijing,
China). The suspension was further diluted at 1:10 in 7H9
broth. Then inoculate 100 μL diluted bacteria suspension
to each well of the plate. Plates were put in a partially
zipped plastic bag which has some filter paper soaked in
sterile water in it. This is to avoid dehydration of the
medium during the incubation. The concentrations of
INH after two-fold serial dilution in the medium is 0.0625,
0.125, 0.25, 0.5, 1, 2, 4, 8 μg/ml and that of EMB is 0, 1.25,
2.5, 5, 10, 20, 40, 80 μg/ml. After the incubation at 37°C
for 1 week, twenty-five microliters of 0.02% resazurin so-
lution was added to each well. Plates were incubated at
37°C for one additional day. A change in color from blue
to pink indicated the growth of bacteria. The minimal in-
hibitory concentration (MIC) was defined as the mini-
mum drug concentration that prevented the color change
in resazurin solution.
Statistical analysis
The data were analyzed by parametric statistical analysis
1-way ANOVA using OriginPro 8 SR4 PC software, ver-
sion 8.0 (Micro-Cal; GE Healthcare). Results are expressed
as means ± SEM. P < 0.05 was considered significant.
Results
Selection of IEDR MTB clinical isolates
Clinical isolates of MTB were collected from several hos-
pitals and local CDCs covering Zhejiang Province, China.
These samples should be representative of the MTB cir-
culating in Zhejiang province as studied previously
[17,18]. The clinical MTB strains were sputum cultures
stored at the State Key Laboratory for Diagnosis
and Treatment of Infectious Diseases (SKL, Hangzhou,
Zhejiang, China). Growth and morphological characteris-
tics of the colonies were used to exclude non-MTBs.
Drug sensitivity assays were carried out on these isolates.
The assay was first validated with standard laboratory
strain H37Rv carried out in duplicates (Figure 1A). The
readout of the duplicated samples under the same
concentrations of streptomycin was the same. The read-
out at the 24-hour time point was similar as the 48-hour
time point. The MIC of H37Rv against streptomycin ob-
tained from the drug sensitivity assay was the same as the
known data. After the validation of the assay, we moved
on to screen for drug-resistant isolates against four first-
line anti-tubercular drugs namely INH, EMB, rifampicin
and streptomycin. Later we choose to focus on the
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Figure 1 Screening for IEDR MTB clinical isolates. 200 MTB isolates from sputum positive culture were subjected to drug sensitivity assay
against INH or EMB. The assay used resazurin as oxidation-reduction indicator. A change in color from blue to pink indicated the growth of
bacteria, and the MIC was defined as the minimum drug concentration that prevented the color change in resazurin solution. (A) H37Rv was
tested in drug sensitivity assay. Assay was carried out in duplicates at each concentration of streptomycin. The upper panel shows the 24-hour
result and the lower panel shows the 48-hour result. Labels were the concentrations of streptomycin in μg/ml after two-fold serial dilution.
(B) Upper panel indicates the strain is resistant to both EMB and INH, and the lower panel indicates the strain is resistant to INH but not EMB.
Labels were the concentrations of the drug EMB or INH in μg/ml after two-fold serial dilution. Letters in green indicate the normal range of
sensitivity. Letters in red indicate clinical level of resistance. (C) A statistical result of drug resistance to INH. Two independent experiments were
carried out and representative data were shown. **, p < 0.01.
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IEDR strains most probably use efflux pumps to generate
drug resistance [5,6,19-21]. As shown in Figure 1B, the
upper panel showed one isolate resistant to both EMBand INH, whereas the lower panel showed another isolate
resistant to INH but susceptible to EMB. Statistical ana-
lysis showed that 22.5% of the clinical isolates turned re-
sistant to INH (Figure 1C). This rate was close to the
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served that over 65% of the INH-resistant isolates harbor
resistance to EMB as well (Figure 1C). Our observation is
consistent to Gupta’s reports that INH- and EMB-drug re-
sistance often parallel which involves efflux-mediated
mechanism [5,6].
Efflux pump inhibitor verapamil reversed drug resistance
of IEDR clinical isolates
Verapamil is a synthesized efflux pump inhibitor. We
first used verapamil to test whether IEDR clinical iso-
lates obtained resistance phenotype via efflux mechan-
ism. If this is the case, combined use of verapamil with
the anti-tubercular drugs should be able to minimize the
resistance. As shown in Figure 2, the MIC of an IEDR
strain, after verapamil treatment, dropped from the level
of clinical resistance to normal. The reversal effect of
verapamil confirmed that the resistance of IEDR isolates
is mediated by efflux pumps. We used all 29 IEDR clin-
ical isolates for verapamil reversal test. The drug resist-
ance was reversed by the combined usage of verapamil
in about 50% of tested IEDR isolates. TET appeared
more potent than verapamil at the doses used. If verap-
amil and TET was used together, there might be an
additive effect on the reversal effect.
Effect of TET on the drug killing of IEDR
TET is a bis-benzylisoquinoline alkaloid, which is the
main active component from the root of S. tetrandra S.
Moore (Figure 3A). It is known that TET acts as a cal-
cium antagonist similar to verapamil, it is yet not clear if
TET is also an efflux pump inhibitor as verapamil
[8,22,23]. We next tested whether TET can reverse drug
resistance in 29 IEDR strains identified in Figure 1B. We
tested the reversal effect of TET on all the isolates and
found 18 IEDR isolates were responsive and 4 were non-
responders. There are 7 isolates failed to be suspendedFigure 2 Verapamil reversed drug resistance in IEDR clinical isolates.
anti-tubercular drugs were added. Shown was one strain displaying reversawell and did not meet the assay standard and were ex-
cluded from reading. Incubation of the IEDR strains
with TET alone did not show that TET had any impact
on the growth rate of the strains. As shown in Figure 2B,
in one of the strains TET reduced the MIC of EMB by
over 64 fold from clinical resistant concentration 80 μg/ml
to a sensitive dose 1.25 μg/ml, and it reduced the MIC
of INH by over 32 fold from 8 μg/ml to 0.25 μg/ml
(Figure 3B). By statistics, 82% of the IEDR strains dis-
played a reversal effect on the MIC after TET treat-
ment (Figure 3C). These data has shown that TET is an
efflux pump inhibitor similar to verapamil. Although
others have shown that TET has an antibacterial activity
against Staphylococcus aureus, as observed in our experi-
ment, TET did not show a direct antibacterial activity
against MTB.
Discussion
In this study, we have for the first time shown that the
natural herbal medicine TET played a similar role as the
synthesized efflux pump inhibitor verapamil and showed
a significant reversal effect on drug resistance in IEDR
clinical isolates. Importantly, our data suggest that com-
bined use of TET with drugs such as INH or EMB may
be a useful strategy to conquer drug resistance in the
majority of patients who were infected by IEDR strains.
This application of TET means a lowered drug dose and
a shortened duration required in the treatment for these
patients.
Efflux pump-mediated drug resistance involves several
circumstances, e.g. a result of an increasement in de novo
synthesis of the pump itself, or activation of a preexisting
efflux pump [24]. Permanent up-regulation of efflux-
pump expression is also possible. For example, it can
occur through mutations in the local repressor gene, in a
global regulatory gene/transcriptional activator, in the pro-
moter region of the efflux-pump gene or mutation inBacteria were incubated with 5 μg/ml verapamil for 24 hours before
l of the drug resistance to both INH and EMB.
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Figure 3 TET reversed drug resistance in IEDR clinical isolates. (A) Chemical structure of TET. (B) A display of one strain showing that the
drug resistance was reversed after TET treatment. Bacteria were incubated with 30 μg/ml TET for 24 hours before anti-tubercular drugs were
added. (C) A statistical result of TET treatment. Two independent experiments were carried out and representative data were shown. **, p < 0.01.
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gene [25]. Recent study has shown that drug tolerance in
replicating mycobacteria can arise through a macrophage-
induced efflux mechanism, which can persist even after
the bacteria leaves the niche [4].
Resistance to INH and EMB often occurs at the same
time [5,13,21]. Consistent with an earlier study wheremore than 85% EMB-resistant isolates showed resistance
to INH, we too have found that there is a parallel resist-
ance between EMB and INH in MTB [21]. Our data
showed that 65% INH-resistant clinical MTB isolates
showed resistance to EMB (Figure 1B). A micro-array
study has at the molecular level shown that both INH
and EMB were able to induce over-expression of a same
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and Rv3065 [6]. In addition, our study showed that in the
presence of an efflux pump inhibitor verapamil, MICs of
INH and EMB of the IEDR strains were switched to nor-
mal at the same time. These data have shown together
that IEDR isolates obtained resistance due to the effect of
the efflux pumps. We did the MTB drug resistance detec-
tion DNA array test (CapitalBio Corporation, Beijing,
China). This test is used to detect mutations in three
genes, i.e. rpoB, katG and inhA. In this kit, mutation sites
in either katG gene or inhA gene was tested for the drug
resistance against INH. In the 29 IEDR isolates, INH re-
sistance mutations were found in one IEDR isolate that
does not respond to TET and five IEDR isolates that did
respond to TET. So there appeared no significant geno-
typic associations of TET responsiveness in these strains.
It is possible that drug resistance mediated by different
mechanisms co-exists in one strain, but efflux pump may
play a more important role [26,27].
Our data showed that TET can reverse drug resistance
in 82% of IEDR clinical isolates of MTB (Figure 3C). Be-
cause IEDR strains account for about 14.5% of all the
200 clinical isolates tested (Figure 1B), the effective rate
of TET among the human population should be 12%
minimal. It still remains to further tested whether there
are other patterns of drug resistance involving efflux
pumps and whether they could too be reversed by TET.
Although other patterns remain fully tested, we did ob-
serve that TET showed a reversal effect in a few INH
single-resistant clinical isolates.
Conclusions
TET may become a novel drug in combating anti-
tubercular drug resistance based on the in vitro data we
have shown. As is known TET is an existing drug used
clinically for different purposes whose safety has been
tested and thus would mitigate a significant amount of
risk. Developing it as a drug for combined usage to treat
tuberculosis would increase the drug efficacy against
drug-resistant MTB isolates, and lower the dose admin-
istered to alleviate side effects.
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